Winhycare Pharma · Hyderabad, India
Peptide API, R&D and Lyophilisation Partner for Europe and the USA
Winhycare Pharma is a life-sciences and pharmaceutical solutions company with a strong focus on pharmaceutical R&D, peptide APIs, lyophilisation and GMP-oriented support, alongside WinHyCare’s medical and laboratory equipment capabilities.
We supply peptide APIs (Semaglutide, Tirzepatide, Retatrutide, Cagrilintide and BPC-157) to pharmaceutical companies, supply our peptide range and custom peptides for research use only, and take client-supplied peptide APIs through lyophilisation to finished vials.
- API we supply
- Semaglutide
- API purity target
- ≥99%
- Dossier support
- US-DMF / CTD Module 3
- Markets
- EU, UK, Switzerland, USA
What Winhycare Pharma does
Four areas of work, run from Hyderabad for pharmaceutical, biotech and research clients in Europe, the USA and worldwide.
- 01
Pharmaceutical R&D support
Peptide process and analytical development, method validation packages and technology transfer, run as a CRDMO engagement around your programme.
CRDMO services → - 02
Peptide APIs and research peptides
Semaglutide is supplied as API to pharmaceutical manufacturers and R&D organisations. Our full peptide range, plus custom peptide synthesis, is supplied for research use only to research organisations and individual researchers.
Peptide range → - 03
Peptide lyophilisation CMO
You supply the peptide or biosimilar; through our manufacturing partner we take it through lyophilisation and vial filling to finished vials. Projects start with engineering or pilot batches.
Lyophilisation services → - 04
GMP-oriented support
GMP documentation and batch records, regulatory dossier support (US-DMF / CTD Module 3) and qualification and validation of injectable facilities.
Documentation and validation → - +
Sister capability: WinHyCare’s medical and laboratory equipment business supplies ultra-low temperature freezers, biomedical freezers, blood bank refrigerators and platelet incubators.
Contract manufacturing
From peptide API to research-ready lyophilised vials
Through our manufacturing partner, we lyophilise and fill peptides and biosimilars into vials: cycle development and optimisation, engineering, pilot and commercial batches, controlled freezing and drying, residual moisture and reconstitution optimisation, and product-specific vial configurations, with dedicated project management.
- Your peptide or biosimilar
- Lyophilisation & vial filling (manufacturing partner)
- Lyophilised vials
Sourcing peptide API from India for Europe or the USA
Importing an active substance into the EU or the US brings its own documentation and GMP obligations. Our buyer guides set them out, with the primary sources linked.
- Peptide API supplier for Europe, the UK and Switzerland →
Written confirmation under Directive 2011/62/EU, EU GMP Part II, ASMF and CEP routes, and what the QP needs.
- Peptide API supplier for the USA →
Type II DMFs, ICH Q7, FDA’s July 2026 peptide guidance changes and establishment registration.
Therapeutic peptide classes
Peptides we supply for research use only, grouped by class. Semaglutide is also supplied as API.
GLP-1 & Incretin Multi-Agonists
GLP-1, GIP and glucagon receptor agonists for metabolic and weight-management research and manufacturing.
Amylin & Co-Agonists
Amylin analogues and co-agonists used alongside incretin therapies for weight management programmes.
Growth & Metabolism
Growth-hormone secretagogues and metabolic peptides for endocrine and metabolic applications.
Regenerative & Repair
Tissue-repair and regenerative research peptides.
Gastrointestinal
Peptides targeting GI indications such as short bowel syndrome and IBS-C.
Peptide API and research peptides (RUO)
Every peptide below is supplied for research use only, to research organisations and individual researchers. Semaglutide is also supplied as API to pharmaceutical manufacturers. For a sequence that is not listed, see custom peptide synthesis; for GMP programmes, our CRDMO services.
| Compound | CAS Number | Indication / Area | Class | Link |
|---|---|---|---|---|
| AmycretinRUO | 3005889-81-3 | Obesity & type 2 diabetes | GLP-1 & Incretin Multi-Agonists | View peptide → |
| AOD-9604RUO | 221231-10-3 | Obesity / lipolysis (research) | Growth & Metabolism | View peptide → |
| BPC-157API + RUO | 137525-51-0 | Tissue repair / GI (research) | Regenerative & Repair | View API → |
| CagrilintideAPI + RUO | 1415456-99-3 | Obesity & weight management | Amylin & Co-Agonists | View API → |
| CJC-1295RUO | 863288-34-0 | Growth-hormone modulation (research) | Growth & Metabolism | View peptide → |
| EloralintideRUO | 2883634-40-8 | Obesity & weight management | Amylin & Co-Agonists | View peptide → |
| LinaclotideRUO | 851199-59-2 | IBS-C & chronic constipation | Gastrointestinal | View peptide → |
| MazdutideRUO | 2259884-03-0 | Obesity & type 2 diabetes | GLP-1 & Incretin Multi-Agonists | View peptide → |
| RetatrutideAPI + RUO | 2381089-83-2 | Obesity & type 2 diabetes | GLP-1 & Incretin Multi-Agonists | View API → |
| SemaglutideAPI + RUO | 910463-68-2 | Type 2 diabetes & chronic weight management | GLP-1 & Incretin Multi-Agonists | View API → |
| SermorelinRUO | 86168-78-7 | Growth-hormone axis research | Growth & Metabolism | View peptide → |
| SurvodutideRUO | 2805997-46-8 | Obesity & MASH (NASH) | GLP-1 & Incretin Multi-Agonists | View peptide → |
| TB-500 (Thymosin Beta-4)RUO | 77591-33-4 | Tissue-repair research (preclinical) | Regenerative & Repair | View peptide → |
| TeduglutideRUO | 197922-42-2 | Short bowel syndrome | Gastrointestinal | View peptide → |
| TesamorelinRUO | 218949-48-5 | HIV-associated lipodystrophy | Growth & Metabolism | View peptide → |
| TirzepatideAPI + RUO | 2023788-19-2 | Obesity & type 2 diabetes | GLP-1 & Incretin Multi-Agonists | View API → |
RUO = research use only: not for human or veterinary use, and not for use in medicinal products. Semaglutide is also supplied as API for pharmaceutical manufacturing and R&D.
Leadership and expertise
Nisar Mohammed
Founder & Managing Director, WinHyCare
Founder and managing director of WinHyCare, which he built with co-founder Moqtar Mohammed. Before founding the company he spent 28 years and 8 months at Dr. Reddy’s Laboratories. He reviews Winhycare Pharma’s technical articles.
Kareem Ahmed Basha
Director & Chief Scientific Officer, Winhycare Pharma
Peptide subject-matter expert at Winhycare Pharma in Hyderabad. He writes the division’s technical content on peptide APIs and lyophilisation and supports client projects.
Insights
All insights →-
CDMO vs CMO vs CRDMO: what is the difference, and which one does a pharma buyer need?
What CMO, CDMO and CRDMO mean in pharma, how their scope differs, what GMP rules apply to every contract manufacturer, and which model a buyer needs.
-
Generic semaglutide: EU and US regulatory pathways, and what API makers must show
How generic semaglutide is filed in the EU and US: generic vs hybrid, 8+2+1 protection, ANDA vs 505(b)(2), synthetic vs recombinant API, API maker duties.
-
How to qualify a peptide API supplier: a documentation and audit checklist for EU and US buyers
A documentation and audit checklist for qualifying a peptide API supplier for EU and US filings: written confirmation, DMF/ASMF, GMP audit, impurities and agreements.
-
Lyophilised peptide stability and storage: how long a peptide API lasts and how to keep it
How long a lyophilised peptide API lasts, what degrades it, which storage temperatures ICH Q1A(R2) defines, how stability is tested and how to ship it safely.
-
Peptide API impurities and specifications: thresholds, tests and what regulators expect in 2026
How peptide API impurities are classified and controlled: why ICH Q3A does not apply, Ph. Eur. 0.1/0.5/1.0% thresholds, FDA's 2026 peptide guidance and what a specification covers.
-
Peptide lyophilisation: a practical guide to freeze-drying peptide APIs
How peptide freeze-drying works: freezing, primary and secondary drying, Tg′ and collapse temperature, excipients, cycle development and vial and stopper choices.
-
How to read a semaglutide API certificate of analysis (COA)
A test-by-test guide to a semaglutide API COA: identity, assay, purity, peptide content, water, acetate, residual solvents, endotoxin and the specs behind them.
-
Semaglutide patent expiry by country: dates, status and what it means for API buyers
When semaglutide's compound protection ends in India, China, Canada, Brazil, the US, EU, UK and Japan, with primary sources, and what it means for API buyers.
-
Semaglutide vs tirzepatide vs liraglutide: how the three peptide APIs compare
How semaglutide, tirzepatide and liraglutide APIs differ: backbone, length, lipid chain, receptors, half-life basis, molecular weight, CAS and approval.
-
SPPS vs LPPS vs hybrid: how peptide APIs are manufactured, and why the route matters to buyers
Solid-phase, liquid-phase and hybrid peptide synthesis compared for API buyers: chemistry, length limits, impurities, scale, solvent use and regulatory impact.
-
What is a peptide API? API vs drug substance explained
A peptide API is the active ingredient of a peptide medicine. How ICH, FDA and EU law define API, drug substance and active substance, and where peptides fit.
Discuss a peptide API or lyophilisation project
Tell us the molecule, quantity and documentation you need, or the API you want lyophilised. Our team will come back to you directly.
Email [email protected] · WhatsApp +91 90005 85863 or +91 88848 99909